

# **Howard Wooding Rogers, M.D.-Ph.D.**

## **HOME ADDRESS**

54 Hilltop Drive

Tel: (860)859-2262

Madison, CT 06443

Fax: (860)859-9819

Email: [rogershoward@sbcglobal.net](mailto:rogershoward@sbcglobal.net)

Cell: (860)917-8842

Practice Website: [advanceddermatologyct.com](http://advanceddermatologyct.com)

## **MEDICAL EXPERIENCE**

2017-Pres. Shoreline Mohs Surgery Guilford, CT

Private Practice Dermatologic Surgery (Owner)

2004-Pres. Advanced Dermatology LLC Norwich, CT

Private Practice General and Surgical Dermatology (Owner)

2000-2004 Chelsea Clinic Surgery Norwich, CT

Private Practice General and Dermatologic Surgery

## **EDUCATION**

2007-2008 Skin Cancer Center Cincinnati, OH

Surgical Fellowship in Mohs Micrographic Surgery

1997-2000 Washington University School of Medicine St. Louis, MO

Dermatology Residency, Chief Resident

1996-1997 University of Maryland Hospital Baltimore, MD

Internship in Internal Medicine

1989-1996 Washington University School of Medicine St. Louis, MO

M.D.-Ph.D. Combined Degree Program

Ph.D. in Immunology

1985-1989 Harvard University Cambridge, MA  
B.S. in Biology, Magna Cum Laude

## **CERTIFICATIONS**

2000, 2010 Board Certified American Board of Dermatology  
2009 Fellow member American College of Mohs Micrographic  
Surgery

## **MEDICAL ASSOCIATIONS AND POSITIONS**

Fellow member American Academy of Dermatology, Fellow member  
American College of Mohs Surgery, American Society of Mohs Surgery,  
American Society of Dermatologic Surgery, Masters Dermatologic  
Association, American Medical Association, Connecticut Dermatology  
Society

## **NATIONAL ASSOCIATION LEADERSHIP**

### **American Academy of Dermatology**

- Chair, Patient Access and Payer Relations Committee 2014-pres
- Chair, Physician Payment Reform Workgroup 2011-2012
- Performance Measures Committee 2013-2018
- Healthcare Finance Committee 2011-2014
- Workgroup on Innovation in Payment and Delivery 2013-present
- Expert Resource Group of Quality and Patient Safety 2013-2015
- Private Sector Advocacy Taskforce 2012-2014
- Deputy Chair, Resource Based Relative Value System Committee 2015-  
present
- Chair, Phototherapy Documentation Workgroup 2016-2017

- Skin Cancer Measure Development Workgroup 2014-2016
- Patient Reported Outcomes Measure Development Workgroup 2016-pres
- Governmental Affairs and Healthcare Policy Council 2017-pres
- Performance Measures Needs Assessment Workgroup 2017-2018
- Chair of Oncology Subcommittee of Centers for Medicare and Medicaid Services Acumen MACRA Resource Use Measure Clinical Committee 2018
- Chair of Dermatologic Care Subcommittee of Centers for Medicare and Medicaid Services Acumen MACRA Resource Use Measure Clinical Committee 2019

### **American College of Mohs Surgery**

- Elected to ACMS Board of Directors 2016-pres
- Chair, Private Sector Task Force 2013-pres
- Scientific Program Committee Cochair 2012, Chair 2013, Ex Officio 2014
- ACMS representative to AMA Relative Value Update Committee (RUC) 2014 –pres
- ACMS National Registry and Outcomes Committee, Vice Chair 2013-pres
- Chair of ACMS Mohs Log Subcommittee 2013-2015
- ACMS representative to Centers for Medicare and Medicaid Services MACRA Resource Use Measure Clinical Committee 2016
- Public Policy Committee 2012-pres
- Alliance for Specialty Medicine (ASM), ACMS Representative 2014-pres
- ACMS Membership Committee 2012-2014

### **American Society of Dermatologic Surgery**

- ASDS Task Force on Value Analysis 2016-pres
- ASDS Alternative Payment Model Workgroup 2014—2015

### **Council of Medical Specialty Societies**

-Representative to the Ambulatory Quality Alliance 2012-2013

## **INDUSTRY POSITIONS**

-Humana Inc., Physician Provider Collaborative Committee, 2013-2016

-Case and policy reviewer for Medical Review Institute of America

## **COMMUNITY SERVICE**

2000-pres. Organized 53 community skin cancer screening programs in conjunction with William W. Backus Hospital

2002-pres. Speaker for community education program in conjunction with William W. Backus Hospital education department

## **CLINICAL RESEARCH**

2001-2003 Phase 3 study site for efalizumab efficacy in psoriasis (Genentech)

2005 Trial study site for community based efficacy study of adapalene for acne (Galderma)

2005-2008. ATLAS study on long term safety of alefacept for psoriasis (Biogen-Idec)

## **HONORS**

2017 American Academy of Dermatology – Presidential Citation for service in insurer and regulatory advocacy

2017 American Academy of Dermatology – Presidential Citation for service as advisor to AMA RUC

2017 American Academy of Dermatology – Performance Measures Pioneer Award

- 2014 Distinguished Service Award, American College of Mohs Surgery
- 1999-2000 Chief Resident, Dermatology Residency, Washington University School of Medicine
- 1996 Henry Yalem Prize in Dermatology, awarded for outstanding work in Dermatology
- 1995 Spencer T. Olin Fellowship in recognition of superior achievement in biomedical research
- 1989-1995 Swazey Scholar for Academic Distinction in Medical Pursuits

**Languages** – English, Spanish

## **PUBLICATIONS**

1. Burd PR, Rogers HW, Gordon JR, Martin CA, Jayaraman S, Wilson S, Dvorak AM, Galli SJ, Dorf ME: Interleukin 3-dependent and independent mast cells stimulated with IgE and antigen express multiple cytokines. *J Exp Med* 170:245-257, 1989.
2. Rogers HW, Sheehan KCF, BruntLM, DowerSK, Unanue ER, Schreiber RD: Interleudin-1 participates in the development of anti-Listeria responses in normal and SCID mice. *Proc Natl Acad Sci USA* 89:1011-1015, 1992.
3. Beckerman KP, Rogers HW, Corbett JA, Schreiber RD, McDaniel ML, Unanue ER: Release of nitric oxide during the T cell independent pathway of macrophage activation. Its roles in resistance to *Listeria monocytogenes*. *J Immunol* 150: 888-895, 1993

4. Rogers HW, Unanue ER: Neutrophils are involved in acute, nonspecific resistance to *Listeria monocytogenes* in mice. *Infect and Immun* 61:5090-5096, 1993.
5. Rogers HW, Tripp CS, Schreiber RD, Unanue ER: Endogenous IL-1 is required for neutrophil recruitment and macrophage activation during murine Listeriosis. *J Immunol* 152:2093-2101, 1994.
6. Rogers HW, Unanue ER: Different stages in the natural and acquired resistance to an intracellular pathogen. *The Immunologist* 3:152-156, 1995.
7. Rogers HW, Callery M, Unanue ER: *Listeria* induces hepatocyte apoptosis: implications for the role of neutrophils in *Listeria* resistance. *J Immunol* 156:679-684, 1996.
8. Coldiron BM, Dinehart S, Rogers HW: Sentinel lymph node biopsy and completion lymph node dissection for malignant melanoma are not standard of care. *Clin. Dermatol.* 2009.
9. Rogers HW, Coldiron BM: A Relative Value Unit Based Cost Comparison of Treatment Modalities for Non-Melanoma Skin Cancer. *J Am Acad Dermatol.* 2009 Jul;61(1):96-103.
10. Rogers HW, Coldiron BM: Sentinel node biopsy not standard of care for melanoma. *J Am Acad Dermatol.* 2011 Feb;64(2):441.
11. Rogers HW, Coldiron BM: Unconflicted. *J Am Acad Dermatol.* 2011 Feb;64(2):437-8.
12. Rogers HW, Weinstock MA, Harris AR, Hinckley MR,

Feldman SR, Fleischer AB, Coldiron BM: Incidence estimate of nonmelanoma skin cancer in the United States, 2006. *Arch Dermatol.* 2010 Mar;146(3):283-7.

13. Rogers HW, Coldiron BM. Analysis of skin cancer treatment and costs in the United States Medicare population, 1996-2008. *Dermatol Surg.* 2013 Jan;39(1 Pt 1):35-42.
14. Rogers HW, Coldiron BM, Dinehart SM, Hendi A, Hruza G, Fosko SW, Moody BR. Skin cancer treatment fee comparisons inaccurate. *Dermatol Surg.* 2012 Dec;38(12):2038-9.
15. Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence estimate of nonmelanoma skin cancer in the United States, 2012. *Arch Dermatol. JAMA Dermatol.* 2015 Oct;151(10):1081-6.
16. Rogers HW. Is cryosurgery cost effective in the treatment of non-melanoma skin cancer? *Dermatological Cryosurgery and Cryotherapy*, Springer, New York, NY. 2016.
17. Rogers HW. Is Mohs Surgery Cost-Effective versus Traditional Surgical Excision? *Current Dermatology Reports: Volume 3, Issue 2 (2014)*, 91-97.
18. Leitenberger JJ, Rogers HW, Chapman JC, Maher IA, Fox MC, Harmon CB, Bailey EC, Wisco OJ. Defining Recurrence of Non-Melanoma Skin Cancer after Mohs Micrographic Surgery: Report of the American College of Mohs Surgery Registry and Outcomes Committee. *J Am*

Acad Dermatol. J Am Acad Dermatol. 2016  
Nov;75(5):1022-1031.

19. Rogers HW. One diagnosis and modifier -25: appropriate or audit target? *Cutis*. 2017 Mar;99(3):165-166.
20. Rogers HW. Phototherapy coding in the time of biologics. *Cutis*. 2017. In press.
21. Tolkachjov SN, Brodland DG, Coldiron BM, Fazio MJ, Hruza GJ, Roenigk RK, Rogers HW, Zitelli JA, Winchester DS, Harmon CB. Understanding Mohs Micrographic Surgery: A Review and Practical Guide for the Nondermatologist. *Mayo Clin Proc*. 2017 Aug;92(8):1261-1271.
22. Rogers HW. Modifier -25 Victory, But the Battle Is Not Over. *Cutis*. 2018 June;101(6):409-410
23. Rogers HW. Practice Expense—Only Codes: No Physician Work, No Sweat. *Cutis*. 2018 Nov;101(6):348-352